Use and Limits of (1-3)-β- d -Glucan Assay (Fungitell), Compared to Galactomannan Determination (Platelia Aspergillus), for Diagnosis of Invasive Aspergillosis
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
This study was undertaken to examine the performance of the Fungitell β-glucan (BG) assay, to compare it with that of the galactomannan (GM) test for the diagnosis of invasive aspergillosis (IA) in patients with hematological malignancies, and to examine the rates of false-positive BG and GM test results due to β-lactam antibiotics among sera of patients with Gram-positive or Gram-negative bacteremia and selected sera with false-positive results from the GM test. Serum samples from 105 patients with proven ( n = 14) or probable ( n = 91) IA, 97 hematology patients at risk for invasive fungal infections, 50 healthy blood donors, and 60 patients with bacteremia were used to study the sensitivities and specificities of the assays. The GM test was more specific than the BG assay (97% versus 82%, respectively; P = 0.0001) and the BG assay was more sensitive than the GM test (81% versus 49%, respectively; P < 0.0001) for IA diagnosis. The study of 49 separate batches of β-lactam antibiotics showed high and very similar rates of false-positive results for the GM and BG assays (29 and 33%, respectively; P = 0.82) but with an almost complete lack of concordance between the 2 assays. For patients with bacteremia, the rate of false-positive results was much higher with the BG test than with the GM test (37% versus 2%, respectively; P < 0.0001), with no significant difference between Gram-positive and Gram-negative bacteremia. In conclusion, the BG test may be useful for the diagnosis of IA because of its high sensitivity in comparison with the GM test, but the overall benefit of this assay remains limited because of its inadequate specificity and its cost.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917 · cited 2×
“Another serum marker for the presence of invasive fungal infections (IFIs) is (1-3)- -D-glucan (BG), which has been included in the relevant European Organization for Research and Treatment of Cancer (EORTC)/Mycoses Study Group (MSG) diagnostic criteria (8).”
MethodDiagnostic tests 4: likelihood ratios
Deeks, J. J., & Altman, D. G. (2004) · BMJ · doi:10.1136/bmj.329.7458.168 · Cited by 1,600 · cited 1×
“The LR summarizes how much more likely patients with IA are to have that particular result (positive or negative for a binary result, or a given result for a multiple-value test) than are patients without IA (controls) (18).”
BackgroundOstrosky-Zeichner, L., Alexander, B. D., Kett, D. H., Vazquez, J., Pappas, P. G., Saeki, F., Ketchum, P. A., Wingard, J., Schiff, R., Tamura, H., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/432470 · Cited by 669
-D-Glucan Assay for the Diagnosis of Invasive Fungal Infections: A Meta-analysis
Karageorgopoulos, D. E., Vouloumanou, E. K., Ntziora, F., Michalopoulos, A., Rafailidis, P. I., & Falagas, M. E. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq206 · Cited by 538
Laboratory diagnosis of invasive aspergillosis
Hope, W., Walsh, T., & Denning, D. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70238-3 · Cited by 495
Cited by
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Kullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315
Diagnosis of invasive fungal infections: challenges and recent developments
Fang, W., Wu, J., Cheng, M., Zhu, X., Du, M., Chen, C., Liao, W., Zhi, K., & Pan, W. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00926-2 · Cited by 356
Dobias, R., Jaworska, P., Tomaskova, H., Kanova, M., Lyskova, P., Vrba, Z., Holub, C., Svobodová, L., Hamal, P., & Raska, M. (2018) · Mycoses · doi:10.1111/myc.12765 · Cited by 42
Zhang, L., Guo, Z., Xie, S., Zhou, J., Chen, G., Feng, J., & Huang, Y. (2019) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.08.005 · Cited by 36
Use of 1,3-β-D-glucan in invasive fungal diseases in hematology patients
Giacobbe, D. R., Del Bono, V., Viscoli, C., & Mikulska, M. (2017) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1401467 · Cited by 27
Special considerations for the diagnosis and treatment of invasive pulmonary aspergillosis
McCarthy, M. W., & Walsh, T. J. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1340835 · Cited by 8
“(n = 91) IA, 97 hematology patients at risk for invasive fungal infections (IFIs), and 50 healthy blood donors [51].”
BackgroundTräger, J., Melichar, V. O., Meyer, R., Rauh, M., Bogdan, C., & Held, J. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0614-8 · Cited by 7
Metadata
- Authors
- Sulahian, A., Porcher, R., Bergeron, A., Touratier, S., Raffoux, E., Menotti, J., Derouin, F., & Ribaud, P.
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2014-07
- Volume
- 52
- Issue
- 7
- Pages
- 2328-2333
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- OpenAlex
- W2089557651
- Cited by
- 125
- References
- 5
- FWCI
- 10.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.